Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapy. Results of the thrombolysis and angioplasty in mycardial infaraction (TAMI) 8 pilot study

Journal of the American College of Cardiology

Volumn 22, Issue 2, 1993, Pages 381-389

  Kleiman, Neal S ^a   Ohman, E Magnus ^a   Califf, Robert M ^a   George, Barry S ^a   Kereiakes, Dean ^a   Aguirre, Frank V ^a   Weisman, Harlan ^a   Schaible, Thomas ^a   Topol, Eric J ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANGIOPLASTY; ARTICLE; FEMALE; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

AGED; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMAN; IMMUNOGLOBULINS, FAB; MALE; MIDDLE AGE; MYOCARDIAL INFARCTION; PILOT PROJECTS; PLATELET AGGREGATION; PLATELET MEMBRANE GLYCOPROTEINS; RECURRENCE; SUPPORT, NON-U.S. GOV'T; THROMBOCYTOPENIA; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0027194452     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(93)90041-X     Document Type: Article

References (43)

1. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial
2. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction
3. The APRICOT Study aspirin versus coumadin in the prevention of recurrent ischemia and reocclusion after successful thrombolysis a placebo-controlled angiogrphic follow-up study
4. Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction
5. 2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator
6. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors
7. 2 modulate the response to tissue-type plasminogen activator in vivo
8. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis
9. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction
10. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs
11. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation
12. Lysis of plasminogen activatorresistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody
13. Activation affects access to the platelet receptor for adhesive glycoproteins
14. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate
15. 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris
16. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis
17. Thrombolysis in Myocardial Infarction (TIMI) Trial Phase I: a comparison between intravenous plasminogen activator and intravenous streptokinase
18. Thrombolysis in Myocardial Infarction (TIMI) Trial. Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
19. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy
20. Pseudothrombocytopenia: manifestation of a new type of platelet agglutinin
21. The pathogenesis of a coronary thrombus
22. The relationship between coronary artery lesions and myocardial infarcts: ulceration of atherosclerotic plaques precipitating coronary thrombosis
23. The relation of coronary thrombosis to ischemic myocardial necrosis
24. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi
25. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction
26. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator
27. Plasmin-induced platelet aggregation and platelet release reaction
28. Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase
29. Plasmin inhibition of platelet function and of arachidonic acid metabolism
30. Tissue plasminogen activator promotes platelet disaggregation in plasma
31. Effects of streptokinase, urokinase, and recombinant tissue plasminogen activator on platelet aggregability and stability of platelet aggregates
32. Co relation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator
33. 1 plus streptokinase in acute myocardial infarction
34. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction
35. Prostacyclin analogue Iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis
36. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction
37. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
38. Relationship of coagulation parameters to patency at 18–48 hours in the thrombolysis in myocardial infarction phase II trial (abstr)
39. The effect of early intravenous heparin on coronary patency, infarct size and bleeding complications after alteplase thrombolysis: results of a randomized double-blind European Cooperative Study Group Trial
40. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion
41. 3
42. 2 antibody with hirudin after rt-PA induced thrombolysis in a chronic canine model of coronary thrombosis (abstr)